Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-)

R Pettitt; E. Matutes; C Dearden; D. Oscier; S. Carruthers; J Dodd; S Dodd; R Jones; A. Rawstrom; S. Agrawal; D. Allsup; A Bloor; J Blundell; S. Devereux; G. Follows; E. Heartin; S Proctor; J. Radford; T. Hamblin; D. Catovsky; P. Hillmen

Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-)

R Pettitt, E. Matutes, C Dearden, D. Oscier, S. Carruthers, J Dodd, S Dodd, R Jones, A. Rawstrom, S. Agrawal, D. Allsup, A Bloor, J Blundell, S. Devereux, G. Follows, E. Heartin, S Proctor, J. Radford, T. Hamblin, D. CatovskyP. Hillmen

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Pages (from-to)	138-139
Number of pages	2
Journal	Haematologica
Volume	94
Issue number	Supplement 2
Publication status	Published - Jun 2009

Cite this

Pettitt, R., Matutes, E., Dearden, C., Oscier, D., Carruthers, S., Dodd, J., Dodd, S., Jones, R., Rawstrom, A., Agrawal, S., Allsup, D., Bloor, A., Blundell, J., Devereux, S., Follows, G., Heartin, E., Proctor, S., Radford, J., Hamblin, T., ... Hillmen, P. (2009). Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-). Haematologica, 94(Supplement 2), 138-139.

@article{31faf55eb91f4c2f9a51d9b8cf184609,

title = "Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-)",

author = "R Pettitt and E. Matutes and C Dearden and D. Oscier and S. Carruthers and J Dodd and S Dodd and R Jones and A. Rawstrom and S. Agrawal and D. Allsup and A Bloor and J Blundell and S. Devereux and G. Follows and E. Heartin and S Proctor and J. Radford and T. Hamblin and D. Catovsky and P. Hillmen",

year = "2009",

month = jun,

language = "Undefined",

volume = "94",

pages = "138--139",

journal = "Haematologica",

issn = "1592-8721",

publisher = "Ferrata Storti Foundation",

number = "Supplement 2",

}

Pettitt, R, Matutes, E, Dearden, C, Oscier, D, Carruthers, S, Dodd, J, Dodd, S, Jones, R, Rawstrom, A, Agrawal, S, Allsup, D, Bloor, A, Blundell, J, Devereux, S, Follows, G, Heartin, E, Proctor, S, Radford, J, Hamblin, T, Catovsky, D & Hillmen, P 2009, 'Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-)', Haematologica, vol. 94, no. Supplement 2, pp. 138-139.

TY - JOUR

T1 - Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-)

AU - Pettitt, R

AU - Matutes, E.

AU - Dearden, C

AU - Oscier, D.

AU - Carruthers, S.

AU - Dodd, J

AU - Dodd, S

AU - Jones, R

AU - Rawstrom, A.

AU - Agrawal, S.

AU - Allsup, D.

AU - Bloor, A

AU - Blundell, J

AU - Devereux, S.

AU - Follows, G.

AU - Heartin, E.

AU - Proctor, S

AU - Radford, J.

AU - Hamblin, T.

AU - Catovsky, D.

AU - Hillmen, P.

PY - 2009/6

Y1 - 2009/6

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000266931900353&KeyUID=WOS:000266931900353

M3 - Article

SN - 1592-8721

VL - 94

SP - 138

EP - 139

JO - Haematologica

JF - Haematologica

IS - Supplement 2

ER -

Results of the phase II NCRI CLL206 trial of Alemtuzumab in combination with high-dose Methylprednisolone for high-risk (17P-)

Other files and links

Cite this